Compare AbCellera Biologics Inc (ABCL) vs EOG Resources Inc (EOG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs EOG Resources Inc — how do they compare? AbCellera Biologics Inc trades at $7.1 (market cap $2.35B), while EOG Resources Inc trades at $138.62 (market cap $71.66B). The key difference: EOG Resources Inc is far larger — about 30.5× AbCellera Biologics Inc's market cap, and EOG Resources Inc pays a 3.03% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | EOG | |
|---|---|---|
Market Cap | $2.35B | $71.66B |
Sector | Health | Energy |
52-Week High | $8.12 | $149.89 |
52-Week Low | $2.78 | $101.78 |
Enterprise Value | $1.99B | $76.12B |
Dividend Yield | — | 3.03% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
EOG Resources trades at $134.54, up 2.88% today, with a bearish technical signal but strong fundamentals including a P/E of 12.72 and net income margin of 23.39%. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 results expected August 5, 2026. Recent news highlights strong free cash flow potential and shareholder returns, while analyst consensus is a Buy with a $157 price target.
The outlook for EOG is positive due to robust profitability, consistent earnings beats, and favorable oil price trends. Key risks include volatile energy markets and high capital expenditures. With no sell ratings from analysts and a price target implying 17% upside, the stock presents a compelling opportunity for value-oriented investors despite near-term technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About EOG Resources Inc
EOG Resources is an oil and gas producer with acreage in several U.S. shale plays, including the Permian Basin, the Eagle Ford, and the Bakken. At the end of 2021, it reported net proved reserves of 3.7 billion barrels of oil equivalent. Net production averaged 829 thousand barrels of oil equivalent per day in 2021 at a ratio of 72% oil and natural gas liquids and 28% natural gas.
Read more on EOG →
